Found: 5000
Select item for more details and to access through your institution.
Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta‑analysis.
- Published in:
- European Journal of Clinical Pharmacology, 2024, v. 80, n. 10, p. 1425, doi. 10.1007/s00228-024-03718-1
- By:
- Publication type:
- Article
MPE beim mutierten NSCLC: Intrapleurale Applikation von Bevacizumab stellt effektive Therapie dar.
- Published in:
- Kompass Onkologie, 2024, v. 11, n. 3, p. 138, doi. 10.1159/000540909
- By:
- Publication type:
- Article
A phase II trial of UGT1A1 genotype-guided FOLFIRI plus bevacizumab as first-line therapy for advanced, unresectable colorectal cancer.
- Published in:
- Oncologist, 2024, v. 29, n. 9, p. 786, doi. 10.1093/oncolo/oyae122
- By:
- Publication type:
- Article
Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.
- Published in:
- Oncologist, 2024, v. 29, n. 9, p. 780, doi. 10.1093/oncolo/oyae121
- By:
- Publication type:
- Article
Informed Managed Care Decision-Making in the Treatment and Management of Ovarian Cancer: Optimizing the Impact of PARP Inhibitors for Improved Outcomes.
- Published in:
- Journal of Managed Care Medicine, 2024, v. 27, n. 2, p. 36
- By:
- Publication type:
- Article
Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story.
- Published in:
- PharmacoEconomics - Open, 2024, v. 8, n. 5, p. 679, doi. 10.1007/s41669-024-00491-w
- By:
- Publication type:
- Article
Optimizing Outcomes: Bevacizumab with Carboplatin and Paclitaxel in 5110 Ovarian Cancer Patients—A Systematic Review and Meta-Analysis.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 8, p. 1095, doi. 10.3390/ph17081095
- By:
- Publication type:
- Article
Off-Label Use of Bevacizumab in Patients Diagnosed with Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 8, p. 1000, doi. 10.3390/ph17081000
- By:
- Publication type:
- Article
Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications.
- Published in:
- Cancers, 2024, v. 16, n. 16, p. 2878, doi. 10.3390/cancers16162878
- By:
- Publication type:
- Article
Comparison of Single-Treatment Efficacy of Bevacizumab and Ranibizumab for Retinopathy of Prematurity.
- Published in:
- Children, 2024, v. 11, n. 8, p. 927, doi. 10.3390/children11080927
- By:
- Publication type:
- Article
In Vitro Physicochemical and Pharmacokinetic Properties of Bevacizumab Dissolved in Silicone Oils Compared to Hydrogel-Substitutes and Porcine Vitreous Bodies.
- Published in:
- Gels (2310-2861), 2024, v. 10, n. 8, p. 501, doi. 10.3390/gels10080501
- By:
- Publication type:
- Article
Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer.
- Published in:
- Wiener Klinische Wochenschrift, 2022, v. 134, n. 19/20, p. 693, doi. 10.1007/s00508-022-02005-2
- By:
- Publication type:
- Article
Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab.
- Published in:
- Wiener Klinische Wochenschrift, 2017, v. 129, n. 9/10, p. 351, doi. 10.1007/s00508-016-1055-0
- By:
- Publication type:
- Article
Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia.
- Published in:
- Wiener Klinische Wochenschrift, 2017, v. 129, n. 3/4, p. 141, doi. 10.1007/s00508-016-1124-4
- By:
- Publication type:
- Article
Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia.
- Published in:
- Wiener Klinische Wochenschrift, 2015, v. 127, n. 15/16, p. 631, doi. 10.1007/s00508-015-0789-4
- By:
- Publication type:
- Article
Differences of frequency in administration of ranibizumab and bevacizumab in patients with neovascular AMD.
- Published in:
- Wiener Klinische Wochenschrift, 2014, v. 126, n. 11/12, p. 355, doi. 10.1007/s00508-014-0539-z
- By:
- Publication type:
- Article
Bevacizumab and sunitinib mediate osteogenic and pro-inflammatory molecular changes in primary human alveolar osteoblasts in vitro.
- Published in:
- Odontology, 2022, v. 110, n. 4, p. 634, doi. 10.1007/s10266-022-00691-y
- By:
- Publication type:
- Article
Cutaneous ulcer with thrombogenic vasculopathy in a patient receiving bevacizumab.
- Published in:
- 2021
- By:
- Publication type:
- case study
Combination of Bevacizumab and NGF Reduces the Risk of Diabetic Retinopathy.
- Published in:
- Cell Biochemistry & Biophysics, 2015, v. 73, n. 1, p. 79, doi. 10.1007/s12013-015-0564-1
- By:
- Publication type:
- Article
Direct Effects of Bevacizumab on Rat Conjunctival Fibroblast.
- Published in:
- Cell Biochemistry & Biophysics, 2015, v. 73, n. 1, p. 45, doi. 10.1007/s12013-015-0565-0
- By:
- Publication type:
- Article
Bevacizumab Inhibits Angiogenesis and Inflammation in Rat Filtration Surgery Model.
- Published in:
- Cell Biochemistry & Biophysics, 2015, v. 73, n. 1, p. 71, doi. 10.1007/s12013-015-0566-z
- By:
- Publication type:
- Article
Zoledronic Acid, Bevacizumab and Dexamethasone-Induced Apoptosis, Mitochondrial Oxidative Stress, and Calcium Signaling Are Decreased in Human Osteoblast-Like Cell Line by Selenium Treatment.
- Published in:
- Biological Trace Element Research, 2018, v. 184, n. 2, p. 358, doi. 10.1007/s12011-017-1187-8
- By:
- Publication type:
- Article
Short-term results of trabeculectomy using adjunctive intracameral bevacizumab: a randomized controlled trial.
- Published in:
- Current Medical Literature: Ophthalmology, 2015, v. 25, n. 2, p. 54
- By:
- Publication type:
- Article
Intravitreal bevacizumab for postoperative recurrent vitreous hemorrhage after vitrectomy for proliferative diabetic retinopathy.
- Published in:
- Current Medical Literature: Ophthalmology, 2014, v. 24, n. 4, p. 126
- By:
- Publication type:
- Article
Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years.
- Published in:
- Current Medical Literature: Ophthalmology, 2014, v. 24, n. 4, p. 128
- By:
- Publication type:
- Article
Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study.
- Published in:
- Current Medical Literature: Ophthalmology, 2014, v. 24, n. 1, p. 32
- By:
- Publication type:
- Article
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
- Published in:
- Current Medical Literature: Ophthalmology, 2014, v. 24, n. 1, p. 24
- By:
- Publication type:
- Article
Intravitreal bevacizumab for the treatment of nonarteritic anterior ischemic optic neuropathy: a prospective trial.
- Published in:
- 2013
- By:
- Publication type:
- Opinion
Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection.
- Published in:
- 2013
- By:
- Publication type:
- Opinion
Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.
- Published in:
- Current Medical Literature: Ophthalmology, 2013, v. 23, n. 2, p. 73
- By:
- Publication type:
- Article
Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-American Collaborative Retina Study Group at 24 months.
- Published in:
- Current Medical Literature: Ophthalmology, 2013, v. 23, n. 2, p. 72
- By:
- Publication type:
- Article
Vitreous, Choroid, and Retina.
- Published in:
- Current Medical Literature: Ophthalmology, 2013, v. 23, n. 1, p. 28
- Publication type:
- Article
External Eye and Cornea.
- Published in:
- Current Medical Literature: Ophthalmology, 2013, v. 23, n. 1, p. 16
- Publication type:
- Article
Vitreous, Choroid, and Retina.
- Published in:
- Current Medical Literature: Ophthalmology, 2011, v. 21, n. 3, p. 112
- Publication type:
- Article
Recommended Reviews.
- Published in:
- Current Medical Literature: Ophthalmology, 2011, v. 21, n. 3, p. 128
- Publication type:
- Article
Vitreous, Choroid, and Retina.
- Published in:
- Current Medical Literature: Ophthalmology, 2010, v. 20, n. 4, p. 148
- Publication type:
- Article
Vitreous, Choroid, and Retina.
- Published in:
- Current Medical Literature: Ophthalmology, 2009, v. 19, n. 2, p. 59
- Publication type:
- Article
Vitreous, Choroid, and Retina.
- Published in:
- 2008
- Publication type:
- Abstract
Uvea.
- Published in:
- Current Medical Literature: Ophthalmology, 2008, v. 18, n. 1, p. 23
- Publication type:
- Article
Long-term Survival, Tolerability, and Safety of First-Line Bevacizumab and FOLFIRI in Combination With Ginsenoside-Modified Nanostructured Lipid Carrier Containing Curcumin in Patients With Unresectable Metastatic Colorectal Cancer.
- Published in:
- Integrative Cancer Therapies, 2022, v. 21, p. 1, doi. 10.1177/15347354221105498
- By:
- Publication type:
- Article
Basic Fibroblast Growth Factor Accumulation in Culture Medium Masks the Direct Antitumor Effect of Anti-VEGF Agent Bevacizumab.
- Published in:
- Doklady Biochemistry & Biophysics, 2024, v. 517, n. 1, p. 285, doi. 10.1134/S1607672924600283
- By:
- Publication type:
- Article
Photo-Modulated Therapeutic Protein Release from a Hydrogel Depot Using Visible Light.
- Published in:
- Angewandte Chemie, 2017, v. 129, n. 4, p. 986, doi. 10.1002/ange.201610618
- By:
- Publication type:
- Article
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 5, p. 463, doi. 10.1007/s10637-008-9127-2
- By:
- Publication type:
- Article
Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 4, p. 393, doi. 10.1007/s10637-008-9125-4
- By:
- Publication type:
- Article
Using Screening for Distress, the Sixth Vital Sign, to advance patient care with assessment and targeted interventions.
- Published in:
- Supportive Care in Cancer, 2012, v. 20, n. 9, p. 2241, doi. 10.1007/s00520-012-1506-8
- By:
- Publication type:
- Article
Vessel size and perfusion-derived vascular habitat refines prediction of treatment failure to bevacizumab in recurrent glioblastomas: validation in a prospective cohort.
- Published in:
- European Radiology, 2023, v. 33, n. 6, p. 4475, doi. 10.1007/s00330-022-09164-w
- By:
- Publication type:
- Article
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
- Published in:
- European Radiology, 2023, v. 33, n. 2, p. 1174, doi. 10.1007/s00330-022-09053-2
- By:
- Publication type:
- Article
Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI.
- Published in:
- European Radiology, 2021, v. 31, n. 8, p. 5640, doi. 10.1007/s00330-020-07647-2
- By:
- Publication type:
- Article
Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article